Lara Iglesias Docampo

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 210 citations · Full text

Medicine, Oncology, Pharmacology +16

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial

Suresh S. Ramalingam, Pasi A. Jänne, Tony Mok et al. · The Lancet Oncology · 2014 · 138 citations

Medicine, Oncology, Pharmacology +9

Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer

Ricardo Hitt, Alicia Lozano, Lara Iglesias Docampo et al. · Oral Oncology · 2022 · 16 citations

Medicine, Oncology, Radiation Oncology +13

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck

Jordi Rubió‐Casadevall, Beatriz Cirauqui, Javier Martínez‐Trufero et al. · Frontiers in Oncology · 2023 · 16 citations · Full text

Medicine, Oncology, Pharmacotherapy +17